A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients

Neuropsychopharmacology

Volumn 28, Issue 8, 2003, Pages 1546-1552

  Oslin, David W ^a,b,c   Berrettini, Wade ^c   Kranzler, Henry R ^d   Pettinati, Helen ^a   Gelernter, Joel ^e   Volpicelli, Joseph R ^a   O'Brien, Charles P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcoholism; Genetics; Naltrexone; Pharmacology; Treatment

Indexed keywords

ASPARAGINE; ASPARTIC ACID; MU OPIATE RECEPTOR; NALTREXONE; PLACEBO;

ABSTINENCE; ALCOHOL CONSUMPTION; ALCOHOLISM; ALLELE; ARTICLE; CONTROLLED STUDY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RELAPSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; ADULT; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETICS; MALE; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK; STATISTICAL MODEL; SURVIVAL;

ADULT; ALCOHOLISM; CONFIDENCE INTERVALS; FEMALE; GENE FREQUENCY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NALTREXONE; ODDS RATIO; POLYMORPHISM, GENETIC; RECEPTORS, OPIOID, MU; SURVIVAL ANALYSIS;

EID: 0041383898     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300219     Document Type: Article

References (50)

1. Anton RF (1996). New methodologies for pharmacological treatment trials for alcohol dependence. Alcoholism: Clin Exp Res 20: 3A-9A.
2. Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias JK et al (2001). Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 21: 72-77.
3. Bergen A, Kokoszka J, Peterson R, Long J, Virkkunen M, Linnoila M et al (1997). Mu-opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry 2: 490-494.
4. Berrettini W, Hoehe M, Ferraro T, DeMaria P, Gottheil E (1997). Human mu opioid receptor gene polymorphisms and vulnerability to substance abuse. Addict Biol 2: 303-308.
5. Bond C, LaForge K, Tian M, Melia D, Zhang S, Borg L et al (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci 95: 9608-9613.
6. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R et al (2000). A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcoholism 35: 587-593.
7. Crowley J, Oslin D, Patkar A, Gottheil E, DeMaria P, O'Brien C et al (2003). A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet.
8. DelBoca F, Kranzler H, Brown J, Korner P (1996). Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. Alcoholism: Clin Exp Res 20: 1412-1417.
9. Franke P, Wang T, Nöthen M, Knapp M, Neidt H, Albrecht S et al (2001). Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet 105: 114-119.
10. Gelernter J, Kranzler H, Cubells J (1999). Genetics of two mu opioid receptor gene (OPRM1) exon 1 polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry 4: 476-483.
11. Gianoulakis C (1996). Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol Alcoholism 31(Suppl 1): 33-42.
12. Gianoulakis C, Krishnan B, Thavundayil J (1996). Enhanced sensitivity of pituitary beta-endorphin to ethanol in subjects at high risk of alcoholism. Arch Gen Psychiatry 53: 250-257.
13. Hernandez-Avila C, Wand G, Luo X, Gelernter J, Kranzler H (2003). Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet 118B: 60-65.
14. Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK et al (2000). Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. 9: 2895-2908.
15. Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O'Malley SS (1996). Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consul Clin Psychol 64: 1044-1053.
16. King AC, Volpicelli JR, Frazer A, O'Brien CP (1997). Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129: 15-22.
17. Kranzler H, Modesto-Lowe V, VanKirk J (2000). Naltrexone vs nefazadone for treatment of alcohol dependence. Neuropsychopharmacology 22: 493-503.
18. Kranzler H, VanKirk J (2001). Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcoholism: Clin Exp Res 25: 1335-1341.
19. Kranzler HR, Gelernter J, O'Malley S, Hernandez-Avila CA, Kaufman D (1998). Association of alcohol or other drug dependence with alleles of the μ-Opioid Receptor Gene (OPRMI). Alcoholism: Clin Exp Res 22: 1359-1362.
20. Kreek MJ (1996). Opiates, opioids and addiction. Mol Psychiatry 1: 232-254.
21. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study G (2001). Naltrexone in the treatment of alcohol dependence. New Engl J Med 345: 1734-1739.
22. Lahiri D, Schnabel B (1993). DNA isolation by a rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet 31: 321-328.
23. Lichtermann D, Franke P, Maier W, Rao M (2000). Pharmacogenics and addiction to opiates. Eur J Pharmacol 410: 269-279.
24. McLellan A, Kushner H, Metzger D, Peters R (1992). The fifth edition of the Addiction Severity Index. J Subst Abuse Treatment 9: 199-213.
25. McLellan AT, Luborsky L, Cacciola J, Griffith J, Evans F, Barr HL et al (1985). New data from the addiction severity index: reliability and validity in three centers. J Nerv Ment Dis 173: 412-423.
26. McLellan AT, Luborsky L, O'Brien CP (1980). An improved evaluation instrument for substance abuse patients: the addiction severity index. J Nerv Ment Dis 168: 26-33.
27. Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP et al (2001). Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10: 258-268.
28. Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI et al (2001). Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcoholism: Clin Exp Res 25: 1634-1647.
29. Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E (2001). Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 96: 1565-1573.
30. Murray C, Lopez A (1996). The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Harvard University Press: Boston.
31. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992). Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49: 881-887.
32. Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J (1997). Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 5: 324-332.
33. Rommelspacher H, Smolka M, Schmidt L, Samochowiec J, Hoehe MR (2001). Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. Alcohol 24: 129-135.
34. Sander T, Gscheidel N, Wendel B, Samochowiec J, Smolka M, Rommelspacher H et al (1998). Human mu-opioid receptor variation and alcohol dependence. Alcoholism: Clin Exp Res 22: 2108-2110.
35. Schinka J, Town T, Abdullah L, Crawford F, Ordorica P, Francis E et al (2002). A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry 7: 224-228.
36. Smolka M, Sander T, Schmidt L, Samochowiec J, Rommelspacher H, Gschiedel N et al (1999). Mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal. Psyhoneuroendocrinology 24: 629-638.
37. Sobell L, Sobell M, Gloria L, Cancilla A (1988). Reliability of a timeline method: assessing normal drinkers reports of recent drinking and a comparative evaluation across several populations. Br J Addict 83: 393-402.
38. Sobell LC, Sobell MB (1992). Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J (eds) Measuring Alcohol Consumption. Humana Press Inc.: Totowa, NJ. pp 41-65.
39. Streeton C, Whelan G (2001). Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcoholism 36: 544-552.
40. Szeto C, Tang M, Lee D, Stadlin A (2001). Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. NeuroReport 12: 1103-1106.
41. Thomas C, Wallack S, Swift R, Bishop C, McCarty D, Simoni-Wastila L (2001). Adoption of naltrexone in alcoholism treatment. J Addict Dis 20: 180.
42. Town T, Abdullah L, Crawford F, Schinka J, Ordorica P, Francis E et al (1999). Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am J Med Genet 88: 458-461.
43. Volpicelli JR (1987). Uncontrollable events and alcohol drinking. Br J Addict 82: 381-392.
44. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992). Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880.
45. Volpicelli JR, Davis MA, Olgin JE (1986). Naltrexone blocks the post-shock increase of ethanol consumption. Life Sci 38: 841-847.
46. Volpicelli JR, O'Brien CP, Alterman AI, Hayashida M (1990). Naltrexone and the treatment of alcohol dependence: initial observations. In: Reid LD (ed) Opioids, Bulimia, and Alcohol Abuse & Addiction. Springer-Verlag: New York. pp 195-214.
47. Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP (1997). BRENDA Manual: Compliance Enhancement Techniques with Pharmacotherapy for Alcohol and Drug Dependence. Guilford press: Philadelphia.
48. Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP (1995). Effect of naltrexone on alcohol 'high' in alcoholics. Am J Psychiatry 152: 613-615.
49. Wand GS, Mangold D, El Deiry S, McCaul ME, Hoover D (1998). Family history of alcoholism and hypothalamic opioidergic activity. Arch Gen Psychiatry 55: 1114-1119.
50. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S et al (2002). The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade. Neuropsychopharmacology 26: 106-114.